Authors
Latest:
Squamous Cell Carcinoma of the Kidney: A Large Case SeriesSyed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.
Latest:
Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and TherapyKhaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.
Latest:
Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLCThe expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
AI and Changing the Future of Pancreatic Cancer ScreeningIn an era where medical records are digitalized, artificial intelligence has the potential to identify patterns that can locate at-risk patients with pancreatic cancer.
Latest:
An Embarrassment of Riches Treatment Sequencing in Gastrointestinal CancersLaura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.
Latest:
CDK4/6 Inhibitor Use May Expand in HR+ HER2– Breast CancerDaniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Circulating Tumor DNA as a Marker of Minimal Residual DiseaseBen Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual disease in colorectal cancer.
Latest:
The Impact of Molecular Testing on Treatment Choices for NSCLCA discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
Latest:
Precision Medicine in NSCLC The Power of Molecular TestingPersonalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.
